Completed OBSERVATIONAL NCT03724994

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer (CHAMP)

Sponsor: Lund University

Conditions Pancreatic Cancer Periampullary Adenocarcinoma Periampullary Cancer

Interventions Gemcitabine

Updated 12 times since 2018 Last updated: Aug 25, 2025 Started: Oct 30, 2018 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03724994, this observational or N/A phase trial focuses on Pancreatic Cancer and Periampullary Adenocarcinoma and remains completed. Sponsored by Lund University, it has been updated 12 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed
May 2025 — Sep 2025 [monthly]

Completed

Status: Recruiting → Completed
Sep 2024 — May 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
May 2024 — Jul 2024 [monthly]

Recruiting

▶ Show 7 earlier versions

May 2022 — May 2024 [monthly]

Recruiting
Dec 2021 — May 2022 [monthly]

Recruiting
Apr 2021 — Dec 2021 [monthly]

Recruiting
Jan 2021 — Apr 2021 [monthly]

Recruiting
Nov 2020 — Jan 2021 [monthly]

Recruiting
Feb 2020 — Nov 2020 [monthly]

Recruiting
Nov 2018 — Feb 2020 [monthly]

Recruiting

First recorded

Oct 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lund University

Data source: Lund University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Malmo, Sweden